|The PTPIA2 beta n/a (Catalog #MBS628196) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The PTPIA2 beta, NT (Receptor-type Tyrosine-protein Phosphatase N2, R-PTP-N2, Islet Cell Autoantigen-related Protein, IAR, ICAAR, Phogrin, PTPRN2, KIAA0387) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s PTPIA2 beta can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB).
Suitable for use in ELISA and Western Blot.
Dilution: ELISA: 1:1,000
Western Blot: 1:100-1:500. Researchers should empirically determine the suitability of the PTPIA2 beta n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
PTPIA2beta is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region, a single transmembrane region, and a single intracellular catalytic domain, and thus represents a receptor-type PTP. The catalytic domain of this PTP is most closely related to PTPRN/IA-2beta. This PTP and PTPRN are both found to be major autoantigens associated with insulin-dependent diabetes mellitus.
Immunogen: Synthetic peptide selected from the N-terminal region of human PTPIA2beta (KLH). In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing PTPIA2 beta are readily searchable from our website. Different antibodies against the same target such as PTPIA2 beta may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.